Table 1 SOF and/or LDV regimens evaluated in the BelloCell System against a genotype 1b HCV replicon cell line.

From: Sofosbuvir (SOF) Suppresses Ledipasvir (LDV)-resistant Mutants during SOF/LDV Combination Therapy against Genotype 1b Hepatitis C Virus (HCV)

 

[Sofosbuvir] (ng/ml)a

[Ledipasvir] (pg/ml)a

0

EC25-SOF

EC50-SOF

EC95-SOF

EC25-LDV

EC25-LDVEC25-SOF

EC25-LDVEC50-SOF

EC25-LDVEC95-SOF

EC50-LDV

EC50-LDVEC25-SOF

EC50-LDVEC50-SOF

EC50-LDVEC95-SOF

EC95-LDV

EC95-LDVEC25-SOF

EC95-LDVEC50-SOF

EC95-LDVEC95-SOF

  1. aConcentrations were determined using a 96-well plate drug screening assay.
Back to article page